ImmunityBio, Inc.
IBRX · XNASCIK 1326110fmd_1DD4P1Y9Q6ZTX9D17XDCV2FQ3GManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2013 to Sep 30, 2026, 52 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 2 | 1 | 1 | 0 | 1 | 15 | 113 |
| Cost of revenue | – | – | – | – | – | – | 0 | 0 | 0 | 1 |
| Realized investment gains (losses) | 0 | 0 | 0 | (0) | (0) | 0 | (0) | 0 | (0) | (0) |
| Gross profit | – | – | – | – | – | – | 0 | 1 | 15 | 113 |
| Research and development | 29 | 42 | 56 | 112 | 140 | 196 | 248 | 232 | 190 | – |
| Selling, general and administrative | 95 | 57 | 43 | 46 | 71 | 135 | 103 | 130 | 169 | – |
| Total operating expenses | 125 | 99 | 98 | 158 | 221 | 331 | 352 | 363 | 359 | – |
| Operating income | (125) | (99) | (98) | (156) | (221) | (330) | (351) | (362) | (344) | (256) |
| Interest expense | 0 | 1 | – | 6 | 9 | 15 | 64 | 129 | 115 | 61 |
| Interest and investment income | 5 | 4 | 2 | 3 | 2 | 1 | 3 | 1 | 2 | 3 |
| Other non-operating income (expense) | 3 | 2 | 2 | (4) | (5) | (20) | (66) | (222) | (69) | (96) |
| Income before taxes | (121) | (97) | (97) | (160) | (226) | (350) | (417) | (584) | (414) | (352) |
| Income tax expense | (1) | (0) | (1) | (0) | (2) | 0 | 0 | (0) | 0 | (0) |
| Net income from continuing operations | (121) | (96) | (96) | (158) | (222) | (350) | (417) | (584) | (414) | (351) |
| Net income | (121) | (96) | (96) | (158) | (222) | (347) | (417) | (583) | (414) | (351) |
| Net income to common shareholders | – | – | – | – | – | – | (417) | (583) | (414) | (351) |